View Author
scopus: 16053612500

Verhoef, G.E.G.

(Gregor Verhoef)


patient treatment response group study survival cytogenetic imatinib blood myeloid leukemia therapy leukemia cytarabine cycle chemotherapy month analysis result cytogenetic response myeloid myeloma trial table phase center donor abnormality level expression hospital chromosome transplantation university combination randomized resistance high-dose cr rate cell transplantation netherland disease remission number toxicity factor induction combination therapy autologou event-free survival outcome cancer death myeloablative i-chop value prognostic effect event-free hematologic progression -833 range psc -833 grade treatment arm allo-sct figure square meter journal melphalan -21 adult randomization ratio hovon relapse bcr-abl count daunorubicin lymphoblastic leukemia




10 Most Recent Publications

High-dose imatinib versus high-dose imatinib in combination with intermediate-dose cytarabine in patients with first chronic phase myeloid leukemia: a randomized phase III trial of the Dutch-Belgian HOVON study group (Article)
Thielen, N. Holt, B. van der Schipperus, M.R. Schattenberg, A.V.M.B. Marwijk Kooy, R. van Smit, W.M. Chu, I.W.T. Valk, P.J.M. Ossenkoppele, G.J. Cornelissen, J.J. Verhoef, G.E.G. Ammerlaan, R.A.H.M. Sonneveld, P. Janssen, J.J.W.M. Deenik, W. Falkenburg, J.H.F. Kersten, M.J. Sinnige, H.
2013-04-10
Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemia (Article)
Deenik, W. Janssen, J.J.W.M. Sonneveld, P. Marwijk Kooy, M. van Wittebol, S. Willemze, R. Wijermans, P.W. Beverloo, H.B. Löwenberg, B. Valk, P.J.M. Ossenkoppele, G.J. Cornelissen, J.J. Holt, B. van der Verhoef, G.E.G. Smit, W.M. Kersten, M.J. Daenen, S.M.G.J. Verdonck, L.F. Ferrant, A. Schattenberg, A.V.M.B.
2010-06-01
High-dose daunorubicin in older patients with acute myeloid leukemia (Article)
Löwenberg, B. Ossenkoppele, G.J. Biemond, B.J. Vellenga, E. Marwijk Kooy, M. van Verdonck, L.F. Beck, J.A. Döhner, H. Gratwohl, A. Pabst, T. Verhoef, G.E.G. Putten, W.L.J. van Schouten, H.C. Graux, C. Ferrant, A. Sonneveld, P. Maertens, J. Jongen-Lavrencic, M. Lilienfeld-Toal, M. Von
2009-09-24
Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: A prospective sibling donor versus no-donor comparison (Article)
Cornelissen, J.J. Holt, B. van der Wijermans, P.W. Biesma, D.H. Wittebol, S. Voogt, P.J. Baars, J.W. Zachée, P. Verdonck, L.F. Löwenberg, B. Dekker, A.W. Verhoef, G.E.G. Veer, M.B. van 't Oers, M.H.J. van Ossenkoppele, G.J. Sonneveld, P. Maertens, J. Marwijk Kooy, M. van Schaafsma, M.R.
2009-02-05
Dose-finding study of imatinib in combination with intravenous cytarabine: Feasibility in newly diagnosed patients with chronic myeloid leukemia (Article)
Deenik, W. Holt, B.D. van Sonneveld, P. Kooy, M.M. van Wittebol, S. Willemze, R. Wijermans, P.W. Westveer, P.H.M. Beverloo, H.B. Valk, P.J.M. Löwenberg, B. Ossenkoppele, G.J. Verhoef, G.E.G. Cornelissen, J.J. Smit, W.M. Kersten, M.J. Kluin-Nelemans, H.C. Verdonck, L.F. Ferrant, A. Schattenberg, A.V.M.B. Janssen, J.J.W.M.
2008-03-01
Intermediate-dose melphalan compared with myeloablative treatment in multiple myeloma: Long-term follow-up of the Dutch Cooperative Group HOVON 24 trial (Article)
Sonneveld, P. Holt, B. van der Westveer, P.H.M. Lokhorst, H.M. Segeren, C.M. Vellenga, E. Croockewit, A.J. Verhoef, G.E.G. Cornelissen, J.J. Schaafsma, M.R. Oers, M.H.J. van Wijermans, P.W.
2007-07-01
CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age (Article)
Heuvel-Eibrink, M.M. van den Holt, B. van der Burnett, A.K. Knauf, W.U. Fey, M. Verhoef, G.E.G. Vellenga, E. Ossenkoppele, G.J. Löwenberg, B. Sonneveld, P.
2007-05-01
Intensified 12-week CHOP (I-CHOP) plus G-CSF compared with standard 24-week CHOP (CHOP-21) for patients with intermediate-risk aggressive non-Hodgkin lymphoma: A phase 3 trial of the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) (Article)
Verdonck, L.F. Notenboom, A. Jong, D. de MacKenzie, M.A. Verhoef, G.E.G. Kramer, M.H.H. Ossenkoppele, G.J. Doorduijn, J.K. Sonneveld, P. Imhoff, G. van
2007-04-01
Abnormalities of chromosome 1p/q are highly associated with chromosome 13/13q deletions and are an adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma (Article)
Wu, K.L. Beverloo, H.B. Lokhorst, H.M. Segeren, C.M. Holt, B. van der Steijaert, M.M. Westveer, P.H.M. Poddighe, P. Verhoef, G.E.G. Sonneveld, P.
2007-02-01
High-vs low-dose cytarabine combined with interferon alfa in patients with first chronic phase chronic myeloid leukemia. A prospective randomized phase III study (Article)
Deenik, W. Holt, B. van der Schouten, H. Löwenberg, B. Ossenkoppele, G.J. Cornelissen, J.J. Verhoef, G.E.G. Schattenberg, A.V.M.B. Verdonck, L.F. Daenen, S.M.G.J. Zachée, P. Westveer, P.H.M. Smit, W.M. Wittebol, S.
2007-02-01
  • rss icon RSS Publication Feed
  • foaf icon FOAF Profile